Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

DocGo (DCGO) EBITDA (2021 - 2025)

Historic EBITDA for DocGo (DCGO) over the last 5 years, with Q3 2025 value amounting to -$28.1 million.

  • DocGo's EBITDA fell 53615.61% to -$28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.5 million, marking a year-over-year decrease of 25920.37%. This contributed to the annual value of $19.7 million for FY2024, which is 15952.0% up from last year.
  • According to the latest figures from Q3 2025, DocGo's EBITDA is -$28.1 million, which was down 53615.61% from -$10.2 million recorded in Q2 2025.
  • Over the past 5 years, DocGo's EBITDA peaked at $23.4 million during Q4 2021, and registered a low of -$28.1 million during Q3 2025.
  • For the 5-year period, DocGo's EBITDA averaged around $2.1 million, with its median value being $3.6 million (2021).
  • In the last 5 years, DocGo's EBITDA skyrocketed by 92150.09% in 2022 and then plummeted by 53615.61% in 2025.
  • Quarter analysis of 5 years shows DocGo's EBITDA stood at $23.4 million in 2021, then crashed by 63.32% to $8.6 million in 2022, then dropped by 3.94% to $8.2 million in 2023, then tumbled by 152.8% to -$4.4 million in 2024, then plummeted by 544.32% to -$28.1 million in 2025.
  • Its EBITDA was -$28.1 million in Q3 2025, compared to -$10.2 million in Q2 2025 and -$8.9 million in Q1 2025.